MoonLake Immunotherapeutics

Helix Acquisition Corp (Nasdaq: HLXA) is a blank-check company that completed its initial public offering in 2021, targeting the healthcare and biopharmaceutical sector. The vehicle pursued a business combination with MoonLake Immunotherapeutics, a clinical-stage company developing nanobody therapies for inflammatory and autoimmune diseases, including its lead candidate sonelokimab, which targets the IL-17A/F pathway. HLXA filed an 8-K with the SEC on February 25, 2022, in connection with the de-SPAC transaction, which ultimately resulted in the combined company listing on Nasdaq under the ticker MLTX. For full filing history, sponsor details, and deal analytics on HLXA and hundreds of other SPACs, sign up for complete access at SpacDesk.